-
Story
Why advocating for your MS is so important -
Press ReleaseNovartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
-
Press ReleaseNovartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis
-
Story
Addressing unmet needs for inherited neuromuscular diseases -
Press ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosis
-
Press ReleaseNovartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
-
Press ReleaseNovartis publishes new five-year efficacy data on Kesimpta® (ofatumumab) for the treatment of relapsing multiple sclerosis
-
Interior PageNeuroscience
-
Press ReleaseNovartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
-
Press ReleaseApplications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMA
-
Press ReleaseNovartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent
-
Story
In neuroscience, “an inflection point in knowledge and technology”